<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096148</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02627</org_study_id>
    <secondary_id>MDA-2004-0342</secondary_id>
    <secondary_id>N01CM62202</secondary_id>
    <secondary_id>N01CM62204</secondary_id>
    <secondary_id>CDR0000391189</secondary_id>
    <nct_id>NCT00096148</nct_id>
  </id_info>
  <brief_title>Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
  <official_title>Randomized Phase II Trial of Idarubicin + Ara-C +/- Bevacizumab in Patients Age &lt; 60 With Untreated Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop&#xD;
      cancer cells from dividing so they stop growing or die. Bevacizumab may stop the growth of&#xD;
      cancer by stopping blood flow to the leukemic cells in the bone marrow. Giving idarubicin and&#xD;
      cytarabine with bevacizumab may kill more cancer cells. It is not yet know whether giving&#xD;
      idarubicin together with cytarabine is more effective with or without bevacizumab in treating&#xD;
      acute myeloid leukemia. This randomized phase II trial is studying how well giving idarubicin&#xD;
      and cytarabine together with bevacizumab works compared to idarubicin and cytarabine alone in&#xD;
      treating patients with newly diagnosed acute myeloid leukemia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Compare the activity of idarubicin and cytarabine with or without bevacizumab in patients&#xD;
      with newly diagnosed acute myeloid leukemia.&#xD;
&#xD;
      II. Compare the proportion of patients who survive and remain in first complete remission&#xD;
      (CR) one year from achieving CR after treatment with these regimens.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Compare the safety of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age (&lt;&#xD;
      45 vs 45 to 59), cytogenetics (normal vs -5/-7 vs other), flt 3 status (normal vs mutated),&#xD;
      and type of acute myeloid leukemia (AML) (de novo vs secondary [arising after cytotoxic&#xD;
      therapy or after an antecedent hematologic disorder, defined as a documented abnormality in&#xD;
      blood count for &gt;= 3 months before diagnosis of AML]. Patients who require treatment before&#xD;
      cytogenetics or flt 3 status is known (e.g., patients with WBC &gt; 50,000 OR with organ&#xD;
      dysfunction thought to be due to blast infiltration) are stratified only according to age and&#xD;
      type of AML. Induction therapy: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      Arm I: Patients receive idarubicin IV over 1 hour on days 1-3 and cytarabine IV continuously&#xD;
      over 24 hours on days 1-4.&#xD;
&#xD;
      Arm II: Patients receive idarubicin and cytarabine as in arm I. Patients also receive&#xD;
      bevacizumab* IV over 30-90 minutes on day 1. Patients who do not achieve complete remission&#xD;
      (CR) after the first induction course may receive a second induction course approximately 28&#xD;
      days* later. Patients who do not achieve CR after 2 courses are removed from the study.&#xD;
&#xD;
      NOTE: *Patients in arm II receive bevacizumab, independently of chemotherapy administration&#xD;
      schedule, once every 21 days for 1 year from CR date.&#xD;
&#xD;
      Post-CR therapy: All patients receive 4 post-CR chemotherapy courses approximately every 28&#xD;
      days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Course 1: Patients receive cytarabine IV continuously over 24 hours on days 1-5.&#xD;
&#xD;
      Course 2 and 4: Patients receive idarubicin IV over 1 hour and cytarabine IV continuously&#xD;
      over 24 hours on days 1-4.&#xD;
&#xD;
      Course 3: Patients receive idarubicin IV over 1 hour and cytarabine IV continuously over 24&#xD;
      hours on days 1-2. After completion of the 4 post-CR chemotherapy courses, patients in arm I&#xD;
      induction therapy do not receive further therapy. Patients in arm II induction therapy&#xD;
      continue to receive bevacizumab as described above.After completion of study treatment,&#xD;
      patients are followed every 3 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60-120 patients (30-60 per treatment arm) will be accrued for&#xD;
      this study within 12-30 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>October 2004</start_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who remain alive in the first complete remission (CR) 1 year from achievement of CR assessed every 3 weeks for 1 year</measure>
    <time_frame>13 months from registration</time_frame>
    <description>Fisher's exact test will be used to compare the proportion of patients alive in CR 13 months from registration date. The test has approximately 89% power to detect an absolute increase of 20% in this proportion, testing at the one-sided 0.15 significance level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of idarubicin+cytarabine+bevacizumab by AdEERS, CBC and chem.</measure>
    <time_frame>Up to 2 years after study completion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Adult Acute Basophilic Leukemia</condition>
  <condition>Adult Acute Eosinophilic Leukemia</condition>
  <condition>Adult Acute Megakaryoblastic Leukemia (M7)</condition>
  <condition>Adult Acute Minimally Differentiated Myeloid Leukemia (M0)</condition>
  <condition>Adult Acute Monoblastic Leukemia (M5a)</condition>
  <condition>Adult Acute Monocytic Leukemia (M5b)</condition>
  <condition>Adult Acute Myeloblastic Leukemia With Maturation (M2)</condition>
  <condition>Adult Acute Myeloblastic Leukemia Without Maturation (M1)</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myelomonocytic Leukemia (M4)</condition>
  <condition>Adult Erythroleukemia (M6a)</condition>
  <condition>Adult Pure Erythroid Leukemia (M6b)</condition>
  <condition>Childhood Acute Basophilic Leukemia</condition>
  <condition>Childhood Acute Eosinophilic Leukemia</condition>
  <condition>Childhood Acute Erythroleukemia (M6)</condition>
  <condition>Childhood Acute Megakaryocytic Leukemia (M7)</condition>
  <condition>Childhood Acute Monoblastic Leukemia (M5a)</condition>
  <condition>Childhood Acute Monocytic Leukemia (M5b)</condition>
  <condition>Childhood Acute Myeloblastic Leukemia With Maturation (M2)</condition>
  <condition>Childhood Acute Myeloblastic Leukemia Without Maturation (M1)</condition>
  <condition>Childhood Acute Myelomonocytic Leukemia (M4)</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <condition>Untreated Adult Acute Myeloid Leukemia</condition>
  <condition>Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies</condition>
  <arm_group>
    <arm_group_label>Arm I (idarubicin, cytarabine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm I: Patients receive idarubicin IV over 1 hour on days 1-3 and cytarabine IV continuously over 24 hours on days 1-4.&#xD;
Post-CR therapy: All patients receive 4 post-CR chemotherapy courses approximately every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Course 1: Patients receive cytarabine IV continuously over 24 hours on days 1-5.&#xD;
Course 2 and 4: Patients receive idarubicin IV over 1 hour and cytarabine IV continuously over 24 hours on days 1-4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (idarubicin, cytarabine, bevacizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive idarubicin and cytarabine as in arm I. Patients also receive bevacizumab* IV over 30-90 minutes on day 1. Patients who do not achieve complete remission (CR) after the first induction course may receive a second induction course approximately 28 days* later. Patients who do not achieve CR after 2 courses are removed from the study.&#xD;
NOTE: *Patients in arm II receive bevacizumab, independently of chemotherapy administration schedule, once every 21 days for 1 year from CR date.&#xD;
Post-CR therapy: All patients receive 4 post-CR chemotherapy courses approximately every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Course 1: Patients receive cytarabine IV continuously over 24 hours on days 1-5.&#xD;
Course 2 and 4: Patients receive idarubicin IV over 1 hour and cytarabine IV continuously over 24 hours on days 1-4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (idarubicin, cytarabine)</arm_group_label>
    <arm_group_label>Arm II (idarubicin, cytarabine, bevacizumab)</arm_group_label>
    <other_name>4-demethoxydaunorubicin</other_name>
    <other_name>4-DMDR</other_name>
    <other_name>DMDR</other_name>
    <other_name>IDA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (idarubicin, cytarabine)</arm_group_label>
    <arm_group_label>Arm II (idarubicin, cytarabine, bevacizumab)</arm_group_label>
    <other_name>ARA-C</other_name>
    <other_name>arabinofuranosylcytosine</other_name>
    <other_name>arabinosylcytosine</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>cytosine arabinoside</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (idarubicin, cytarabine, bevacizumab)</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody</other_name>
    <other_name>anti-VEGF monoclonal antibody</other_name>
    <other_name>Avastin</other_name>
    <other_name>rhuMAb VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (idarubicin, cytarabine)</arm_group_label>
    <arm_group_label>Arm II (idarubicin, cytarabine, bevacizumab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed acute myeloid leukemia (AML)&#xD;
&#xD;
               -  No acute promyelocytic leukemia&#xD;
&#xD;
               -  None of the following cytogenetic abnormalities*:&#xD;
&#xD;
                    -  t(8;21)&#xD;
&#xD;
                    -  t(16;16)&#xD;
&#xD;
                    -  inv(16)&#xD;
&#xD;
          -  No history or clinical evidence of primary brain tumors or brain metastasis&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  No bleeding diathesis or coagulopathy (unless related to AML)&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 2.0 times ULN&#xD;
&#xD;
          -  No proteinuria&#xD;
&#xD;
          -  No more than 1 g of protein on 24-hour urine collection&#xD;
&#xD;
          -  LVEF ≥ 50%&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No New York Heart Association class II-IV congestive heart failure&#xD;
&#xD;
          -  No serious cardiac arrhythmia requiring medication&#xD;
&#xD;
          -  No peripheral vascular disease ≥ grade II&#xD;
&#xD;
          -  No stroke within the past 6 months&#xD;
&#xD;
          -  No arterial thromboembolic event within the past 6 months, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Transient ischemic attack&#xD;
&#xD;
               -  Cerebrovascular accident&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
          -  No other clinically significant cardiovascular disease&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 3-4 months&#xD;
             after study participation&#xD;
&#xD;
          -  No serious or non-healing wound ulcer or bone fracture&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No significant traumatic injury within the past 28 days&#xD;
&#xD;
          -  No known hypersensitivity to Chinese hamster ovary cell products or other recombinant&#xD;
             human antibodies&#xD;
&#xD;
          -  No history or clinical evidence of CNS disease (e.g., seizures not controlled with&#xD;
             standard medical therapy)&#xD;
&#xD;
          -  Prior or concurrent transfusions or hematopoietic growth factors for AML allowed&#xD;
&#xD;
               -  No concurrent prophylactic hematopoietic colony-stimulating factors&#xD;
&#xD;
          -  Prior or concurrent hydroxyurea for AML allowed&#xD;
&#xD;
          -  More than 28 days since prior major surgery or open biopsy&#xD;
&#xD;
          -  No concurrent major surgery&#xD;
&#xD;
          -  No other prior therapy for AML&#xD;
&#xD;
          -  No concurrent full-dose anticoagulation therapy&#xD;
&#xD;
               -  Concurrent prophylactic anticoagulation (e.g. low-dose warfarin to maintain&#xD;
                  patency of permanent indwelling IV catheters) allowed provided INR &lt; 1.5&#xD;
&#xD;
          -  No other concurrent anticancer therapies&#xD;
&#xD;
          -  No other concurrent investigational cytotoxic agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srdan Verstovsek</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 9, 2004</study_first_submitted>
  <study_first_submitted_qc>November 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2004</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Monocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Megakaryoblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Erythroblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Basophilic, Acute</mesh_term>
    <mesh_term>Leukemia, Eosinophilic, Acute</mesh_term>
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

